<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group|1</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">9010043</article-id><article-id pub-id-type="pmc">2063260</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fukuoka</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Masuda</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Negoro</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Matsui</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yana</surname><given-names>T.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kudoh</surname><given-names>S.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kusunoki</surname><given-names>Y.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Takada</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kawahara</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ogawara</surname><given-names>M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kodama</surname><given-names>N.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kubota</surname><given-names>K.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Furuse</surname><given-names>K.</given-names></name></contrib></contrib-group><aff>Department of Internal Medicine, Osaka Prefectural Habikino Hospital, Japan.</aff><pub-date pub-type="ppub"><year>1997</year></pub-date><volume>75</volume><issue>2</issue><fpage>306</fpage><lpage>309</lpage><abstract><p>Sixty-three patients with extensive-stage small-cell lung cancer were randomized to receive either cyclophosphamide, vincristine, doxorubicin and etoposide (CODE) alone or CODE plus recombinant human granulocyte colony-stimulating factor (rhG-CSF). rhG-CSF administration in support of CODE chemotherapy resulted in increased mean total received dose intensity for all drugs (P = 0.03) with a significant improvement in survival (P = 0.004).</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00179-0154.tif" xlink:title="scanned-page" xlink:role="306" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00179-0155.tif" xlink:title="scanned-page" xlink:role="307" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00179-0156.tif" xlink:title="scanned-page" xlink:role="308" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00179-0157.tif" xlink:title="scanned-page" xlink:role="309" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

